METASTATIC BRAIN DAMAGE IN MELANOMA. A CLINICAL CASE OF THE POSSIBILITIES FOR THE SYNERGY OF RADIATION THERAPY WITH SYSTEMIC TREATMENT AND A LITERATURE REVIEW

I.I. Khusainova, P.L. Baldin, A.S. Gizzatullin, A.D. Khaziev, A.N. Kashapova

Naberezhnye Chelny Branch of the Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal, Naberezhnye Chelny

Khusainova Ilyuza I. ― Cand. of Sci. (Med.), radiotherapist of the radiological department of the Naberezhnye Chelny Branch of the Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal

18A Naberezhnochelninskiy Ave., Naberezhnye Chelny, 423803, Russian Federation, tel. +7-987-236-31-44, e-mail: kh.ilyuza@gmail.com, SPIN-код: 2126-1310, Researcher ID: 8425-2023, ORCID ID: 0000-0002-1655-2905

Abstract. Melanoma is a malignant neoplasm requiring complex management of patients. The surgical method remains the main treatment for the majority of patients with an early stage of the disease. Radiation therapy plays an active role in the management of patients with advanced stages and is the basis for effective treatment of solid brain metastases. Immunotherapy improves patient survival when the process spreads. Targeted therapy is a viable alternative for patients unable to continue immunotherapy or with poor immunotherapy outcomes.

Key words: metastatic melanoma, brain metastases, radiation therapy, combination of targeted and immunotherapy, BRAF mutation.